AURX Stock Analysis
AU
Uncovered
Nuo Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Nuo Therapeutics, Inc. engages in the development and sale of biomedical products for chronic wound care. The company is headquartered in Houston, Texas. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel, which harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercialize cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The firm's commercial offering consists of a point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix, which produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.